An observational study in Pregnancy Related and Atopic Dermatitis, sponsored by Incyte Corporation. Recruiting at 1 site in United States. Open to female participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Incyte Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Dermatitis, Atopic by Incyte Corporation — 2 open to participants now, 3 under way, 1 of them phase 3. Dermatitis, Atopic · Incyte Corporation.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is one of 4 that started in 2023, is one of 3 observational ones, and was the 15th registered.
1,592 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies in Dermatitis, Atopic by Incyte Corporation are open now, in 1 country. Recruiting first, the newest first:
Incyte Corporation · Sites in United States
Ages 15–50 · Women only
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 14 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,621 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 90 across the 14 interventional studies, 958 across the 3 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Dermatitis, Atopic by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06627335Incyte CorporationAn Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis | 2027-08-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
Exposure cohort study of women within the US with atopic dermatitis (AD) who were exposed to ruxolitinib cream at any time during their pregnancy period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ruxolitinib Cream
Drug: TCS
Ruxolitinib Cream
Also known as: Opzelura
Topical corticosteroid
Number of major congenital malformation (MCM)s
Defined as any major structural or chromosomal defect in live-born infants, stillbirths or spontaneous losses equal to or greater than 20 weeks' gestation, or electively terminated pregnancies of any gestational age.
Time frame: Up to 12 months after birth
Number of small-for-gestational age (SGA) births
Defined as a birthweight at or below the 10th percentile for a given gestational age.
Time frame: At time of delivery
Number of Pregnancy outcomes
Number of live births, still births, recognized spontaneous abortions and number of elective terminations as defined in the protocol.
Time frame: Up to birth
Plan to share: No
Started Mar 2023 (actual). Primary completion is estimated for Aug 2027, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.